These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 14712466

  • 1. Multicentric Castleman's disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury?
    Seida A, Wada J, Morita Y, Baba M, Eguchi J, Nishimoto N, Okino T, Ichimura K, Yoshino T, Makino H.
    Am J Kidney Dis; 2004 Jan; 43(1):E3-9. PubMed ID: 14712466
    [Abstract] [Full Text] [Related]

  • 2. Pathological findings of progressive renal involvement in a patient with TAFRO syndrome.
    Saito H, Tanaka K, Fujiwara M, Iwasaki T, Numata T, Oda A, Kanno M, Tanaka M, Eiro M, Satoh M, Kazama JJ.
    CEN Case Rep; 2019 Nov; 8(4):239-245. PubMed ID: 31077056
    [Abstract] [Full Text] [Related]

  • 3. An autopsy case of TAFRO syndrome with membranoproliferative glomerulonephritis-like lesions.
    Hashimoto K, Sano T, Honma Y, Ida M, Tominaga H, Sawada A, Abe T, Takahashi H, Shimada Y, Masaki T, Kamata M, Naito S, Aoyama T, Takeuchi Y, Akiya M, Inukai M, Nakata N.
    CEN Case Rep; 2019 Feb; 8(1):48-54. PubMed ID: 30244358
    [Abstract] [Full Text] [Related]

  • 4. Renal thrombotic microangiopathy associated with multicentric Castleman's disease. Report of two cases.
    Lajoie G, Kumar S, Min KW, Silva FG.
    Am J Surg Pathol; 1995 Sep; 19(9):1021-8. PubMed ID: 7661275
    [Abstract] [Full Text] [Related]

  • 5. TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review.
    Nagayama Y, Yamano M, Yagame M, Nariyama T, Takahashi M, Kawamoto M, Matsui K.
    BMC Nephrol; 2019 Oct 17; 20(1):375. PubMed ID: 31623576
    [Abstract] [Full Text] [Related]

  • 6. Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review.
    Leurs A, Gnemmi V, Lionet A, Renaud L, Gibier JB, Copin MC, Hachulla E, Hatron PY, Launay D, Fajgenbaum D, Terriou L.
    Front Immunol; 2019 Oct 17; 10():1489. PubMed ID: 31316523
    [Abstract] [Full Text] [Related]

  • 7. Membranoproliferative glomerulonephritis associated with multicentric angiofollicular lymph node hyperplasia. Case report and review of the literature.
    Said R, Tarawneh M.
    Am J Nephrol; 1992 Oct 17; 12(6):466-70. PubMed ID: 1292348
    [Abstract] [Full Text] [Related]

  • 8. Resolution of membranoproliferative glomerulonephritis complicating angiofollicular lymph node hyperplasia (Castleman's disease).
    Chan TM, Cheng IK, Wong KL, Chan KW.
    Nephron; 1993 Oct 17; 65(4):628-32. PubMed ID: 8302422
    [Abstract] [Full Text] [Related]

  • 9. Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease.
    Menegato MA, Canelles MF, Tonutti E, Pizzolitto S.
    Clin Nephrol; 2004 May 17; 61(5):352-6. PubMed ID: 15182131
    [Abstract] [Full Text] [Related]

  • 10. Castleman's disease and mesangial proliferative glomerulonephritis: the role of interleukin-6.
    Lui SL, Chan KW, Li FK, Cheng IK, Chan TM.
    Nephron; 1998 May 17; 78(3):323-7. PubMed ID: 9546694
    [Abstract] [Full Text] [Related]

  • 11. A case of multicentric Castleman's disease with membranoproliferative glomerulonephritis type 3-like lesion.
    Nagai K, Usui J, Noguchi K, Unai K, Hiwatashi A, Arakawa Y, Togashi A, Morito N, Saito C, Yoh K, Tsuruoka S, Kojima H, Aita K, Nagata M, Yamagata K.
    Pathol Int; 2011 Nov 17; 61(11):686-90. PubMed ID: 22029682
    [Abstract] [Full Text] [Related]

  • 12. Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node.
    Nishi J, Maruyama I.
    Leuk Lymphoma; 2000 Jul 17; 38(3-4):387-94. PubMed ID: 10830746
    [Abstract] [Full Text] [Related]

  • 13. Association of vascular endothelial growth factor and renal thrombotic microangiopathy-like lesions in patients with Castleman's disease.
    Sun PP, Yu XJ, Wang SX, Zhou XJ, Qu L, Zhang F, Ma YY, Liu G, Yang L.
    Nephrology (Carlton); 2020 Feb 17; 25(2):125-134. PubMed ID: 31264312
    [Abstract] [Full Text] [Related]

  • 14. A case of Takayasu arteritis complicated with glomerulonephropathy mimicking membranoproliferative glomerulonephritis: a case report and review of the literature.
    Kuroda T, Ueno M, Sato H, Murakami S, Sakatsume M, Nishi S, Nakano M, Gejyo F.
    Rheumatol Int; 2006 Nov 17; 27(1):103-7. PubMed ID: 16830159
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.
    Saiki R, Katayama K, Hirabayashi Y, Oda K, Fujimoto M, Murata T, Nakajima A, Dohi K.
    BMC Nephrol; 2021 Jun 09; 22(1):216. PubMed ID: 34107915
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease.
    Nishi J, Arimura K, Utsunomiya A, Yonezawa S, Kawakami K, Maeno N, Ijichi O, Ikarimoto N, Nakata M, Kitajima I, Fukushige T, Takamatsu H, Miyata K, Maruyama I.
    Br J Haematol; 1999 Mar 09; 104(3):482-5. PubMed ID: 10086783
    [Abstract] [Full Text] [Related]

  • 20. Fibrillary glomerulonephritis in Castleman's disease.
    Miadonna A, Salmaso C, Palazzi P, Elli A, Braidotti P, Lambertenghi Deliliers G.
    Leuk Lymphoma; 1998 Jan 09; 28(3-4):429-35. PubMed ID: 9517516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.